Abstract: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals.

Abstract: Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which have growth hormone releasing activity in humans or animals

Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.

Abstract: An object of the present invention is to provide a novel agent for the treatment of bone diseases which can shorten a period for curing various fractures including acceleration of bone formation for bone defect, can improve bone strength of united bones and can also improve reduced bone strength accompanied by various diseases. The agent comprises as an effective ingredient a basic fibroblast growth factor and/or its analogue.

Abstract: The present invention relates to a crosslinked gelatin gel preparation containing a basic fibroblast growth factor hereinafter referred to as bFGF wherein a crosslinked gelatin gel is used as a sustained release carrier, and which have different water content, i.e. in vivo degradation and absorption by varying the condition for preparing the crosslinked gelatin gel. By the crosslinked gelatin gel preparation of the present invention, the sustained release rate of bFGF can be varied as required and the durability of in vivo activity of bFGF can be controlled.

Abstract: Tetrahydroquinoline compounds of general formula (I) or pharmacologically acceptable salts thereof, which have a specific and strong binding affinity for AR, exhibit AR agonism or antagonism, have therapeutic effects on AR-mediated diseases, particularly by not acting excessively on the prostate as AR agonists, but by showing potent action on skeletal muscle tissue and bone tissue; and pharmaceutical compositions comprising the compounds or the salts as active ingredients:

Abstract: It provides a gene-entrapping liposome preparation which can be preserved over a long period of time, and a process for the preparation of the same. The preparation can be prepared by adding an aqueous solution of disaccharide to gene-entrapping liposomes. The frozen preparation can be preserved for 6 months or more at preservation temperature of −20° C., and the preparation shows excellent restoration ability in water and does not show reduction in biological activity. In the case of the lyophilized preparation, it can be preserved for longer time of about 1 year, shows excellent restoration ability in water, and does not show reduction in biological activity.

Abstract: A-syringe for storing a freeze-dried agent therein under reduced pressure as well as a method for manufacturing the syringe. A specified amount of a chemical is injected into a cartridge with the one end of the cartridge down. The gasket is plugged halfway on the other end side of the cartridge, so that the cartridge is made communicating between inside and outside by the recessed groove, in which state the chemical is freeze-dried. The sealing cap is overlaid on an upper end face of the gasket and the sealing cap is pushed in the reduced-pressure atmosphere so that the other end side of the cartridge is sealed by the gasket and the sealing cap. The sealing cap is engaged with an end face of the cartridge on the other end side, thereby being prevented from moving into the cartridge.

Abstract: 2-Sulfamoylbenzoic acid derivatives of general formula (I): which have both an antagonistic effect on the leukotriene D4 receptor and an antagonistic effect on the thromboxane A2 receptor and salts thereof, pharmaceuticals, anti-allergic agents and leukotriene-thromboxane A2 antagonistic agents containing them as an active ingredient.

Abstract: 2-Sulfamoylbenzoic acid derivatives of general formula (I): which have both an antagonistic effect on the leukotriene D4 receptor and an antagonistic effect on the thromboxane A2 receptor and salts thereof, pharmaceuticals, anti-allergic agents and leukotrienethromboxane A2 antagonistic agents containing them as an active ingredient.

Abstract: Disclosed are dry flowables containing polyoxin compound, surfactant and water-soluble inorganic material. The dry flowables of the present invention have good friability, dispersibility and suspensibilitv when mixed with water, and have an excellent characteristic that they can efficiently bring out the activity of polyoxin compounds as agricultural chemicals.

Abstract: The present invention provides an industrial process for efficiently preparing a 3-(substituted phenyl)-5-isopropylidene-1,3-oxazolidine-2,4-dione derivative having a potent herbicidal activity without using phosgene or the like. The present invention relates to a process for preparing a 3-(substituted phenyl)-5-alkylidene-1,3-oxazolidine-2,4-dione derivative represented by general formula (III), which comprises reaction of an N-(substituted phenyl)carbamate represented by general formula (I) with a 2-hydroxy-3-alkenoate represented by-general formula (II) or with a 3-alkoxy-2-hydroxyalkanoate represented by general formula (IV): ##STR1## (wherein Ar is a substituted phenyl group, R.sup.1 is an alkyl group having a carbon number of from 1 to 6, R.sup.2 and R.sup.3 are independently hydrogen atoms or alkyl groups having carbon numbers of from 1 to 12, and R.sup.4 and R.sup.5 are independently alkyl groups having carbon numbers of from 1 to 6).

Abstract: Disclosed are ursodeoxycholic acid derivatives having an increased solubility in water, and methods for producing the derivatives. To produce the derivatives, ursodeoxycholic acid is protected at its carboxyl group with a benzyl group, then reacted with tetrabenzyl-acetic acid-oxyglucoside of the following formula (1), and de-benzylated; or ursodeoxycholic acid is protected at its hydroxyl group with a t-butyldimethylsilyl group, then reacted with tetrabenzyl-2-hydroxyethyloxyglucoside of the following formula (2), and de-t-butyldimethylsilylated and de-benzylated.

Abstract: A process for preparing 4-methylenepiperidine having a formula (VII): ##STR1## which comprises reacting an isonipecotate having a formula (I): ##STR2## wherein R.sup.1 is methyl group or ethyl group, with an acylating agent having a formula (II): R.sup.2 X or a formula (II'): (R.sup.2).sub.2 O wherein R.sup.2 is benzoyl group or acetyl group and X is chlorine atom or bromine atom, in the presence or the absence of a base, reducing the resulting ester having a formula (III): ##STR3## wherein R.sup.1 and R.sup.2 are the same as defined above, with sodium borohydride or lithium borohydride in an organic solvent containing methanol, reacting the resulting alcohol with a halogenating agent without any solvent or in an organic solvent in the presence or the absence of a base, reacting the resulting halide with a dehydrohalogenating agent in an organic solvent and hydrolyzing the resulting methylene compound having a formula (VI): ##STR4## wherein R.sup.

Abstract: A thiophene derivative containing a phenylamidino group represented by the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are the same or different from each other and are hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxyl group having 1 to 4 carbon atoms; or a pharmacologically acceptable salt thereof. The compound is useful for the treatment of inflammatory diseases.

Abstract: The present invention relates to a method for treating diseases of periodontal tissue by administering a basic fibroblast growth factor, by which the tissue injury is treated to induce regeneration, curing or new attachment.

Abstract: There is disclosed a fungicide containing, as an effective ingredient, a compound having the general formula (I): ##STR1## or an acid addition salt thereof, particularly the compound wherein an absolute configuration of the asymmetric carbon atoms is R,R-configuration or an acid addition salt thereof.

Abstract: This invention provides with novel hydantoin derivatives, processes for preparing them, and herbicides containing said derivatives as active ingredient.

Abstract: The present invention relates to a preparation, particularly a topical preparation, for the therapy of wounds or hemorrhoids, which contains, as an active ingredient, at least one of prostaglandin I.sub.2, prostaglandin E.sub.1 and derivatives of these, particularly beraprost, a derivative of prostaglandin I.sub.2, or a salt thereof, and a method of the therapy of wounds or hemorrhoids, which comprises administering the above active ingredient.

Abstract: A taxoid derivative wherein sugar is combined with any one of paclitaxel, docetaxel and 10-deacetyl-bacatin III via a spacer. A method of producing the taxoid derivative comprises protecting hydroxyl groups at specific position of paclitaxel or docetaxel by protective compound followed by reacting with tetrabenzyl acetyloxyglucoside, and then carrying out debenzyl and detriethylsilyl reactions. A method of producing the taxoid derivative comprises reacting paclitaxel or docetaxel with tetrabenzyl acetyloxyglucoside, and then carrying out debenzyl reaction.